CCF Announces Partnership with Clarified Precision Medicine
TAMPA, FL, US: The Carcinoid Cancer Foundation (CCF) and Clarified Precision MedicineTM have partnered to offer neuroendocrine tumor (NET) patients the opportunity to receive an expert review of their tumor sequencing results from any commercially available test, e.g., FoundationOne CDx, Guardant 360, Caris MI Profile. Each patient is eligible to receive, at no cost to them, a ClarifiedSelectTM analysis, for which nationally recognized precision oncology experts provide a ranked list of FDA-approved treatments, off-label therapies, and clinical trials based on their specific tumor DNA. Every ClarifiedSelectTM report is reviewed by members of Clarified Precision Medicine’s Clinical Network to provide a clear, concise, medically-relevant summary of treatment options for patients and their physicians.
“Precision medicine has shown great potential to extend survival and improve patients’ quality of life,” explains Jody Simon, CEO of Clarified Precision MedicineTM. “Patients living with rare cancers, such as NETs, are often not prioritized and may benefit from targeted therapies. In the case of Clarified, our experts can quickly and effectively determine appropriate treatment options based on clinical experience applying tumor sequencing reports to thousands of patients over the course of their careers.”
Precision oncology is an increasingly important field of medicine which provides information that helps physicians select the best treatments for their patients utilizing genetic or molecular profiling of tumors to identify targetable alterations.
